Bordetella pertussis can act as adjuvant as well as inhibitor of immune responses to non-replicating nasal vaccines

被引:8
作者
Haugan, A
Dao, PXT
Glende, N
Bakke, H
Haugen, IL
Janakova, L
Berstad, AKH
Holst, J
Haneberg, B
机构
[1] Norwegian Inst Publ Hlth, Div Infect Dis Control, N-0403 Oslo, Norway
[2] Haukeland Hosp, N-5021 Bergen, Norway
[3] Univ Oslo, Inst Pharm, Dept Microbiol, Oslo, Norway
关键词
B; pertussis; influenza virus; cholera toxin;
D O I
10.1016/S0264-410X(03)00558-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In mice immunised intranasally with an inactivated whole-virus influenza (INV) vaccine, or ovalbumin (OVA), formalin-inactivated Bordetella pertussis (Bp) augmented antibody responses to the same degree as did cholera toxin (CT) when simply being mixed with INV or OVA. In order to study possible non-carrier effects of mucosal adjuvants, mice were given Bp or CT intranasally 1 day before or 1 day after the INV vaccines. At high antigen doses, both Bp and CT had an adjuvant effect on antibodies in serum also when given 1 day after the vaccine. However, Bp and CT inhibited such antibody responses in serum and saliva when given 1 day ahead of the vaccine. This inhibitory effect was most marked at low antigen doses, i.e. when the adjuvant effect was less obvious. In that event, Bp also inhibited responses in serum and saliva when given 1 day after the INV vaccine. The inhibition of these responses may thus depend on Bp and CT themselves being strongly immunogenic, and competing with INV for the functional capacity of the mucosal immune system. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:7 / 14
页数:8
相关论文
共 28 条
[1]   LOCAL AND SYSTEMIC ANTIBODY-RESPONSES TO DEXTRAN-CHOLERA TOXIN B-SUBUNIT CONJUGATES [J].
BERGQUIST, C ;
LAGERGARD, T ;
LINDBLAD, M ;
HOLMGREN, J .
INFECTION AND IMMUNITY, 1995, 63 (05) :2021-2025
[2]   Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate [J].
Bergquist, C ;
Lagergard, T ;
Holmgren, J .
INFECTION AND IMMUNITY, 1997, 65 (05) :1579-1583
[3]  
Berstad AKH, 1997, VACCINE, V15, P1473
[4]   Inactivated meningococci and pertussis bacteria are immunogenic and act as mucosal adjuvants for a nasal inactivated influenza virus vaccine [J].
Berstad, AKH ;
Andersen, SR ;
Dalseg, R ;
Dromtorp, S ;
Holst, J ;
Namork, E ;
Wedege, E ;
Haneberg, B .
VACCINE, 2000, 18 (18) :1910-1919
[5]  
Dalseg R, 1996, VACCINES, P177
[6]   Outer membrane vesicles from group B meningococci are strongly immunogenic when given intranasally to mice [J].
Dalseg, R ;
Wedege, E ;
Holst, J ;
Haugen, IL ;
Hoiby, EA ;
Haneberg, B .
VACCINE, 1999, 17 (19) :2336-2345
[7]   MUCOSAL IMMUNOADJUVANT ACTIVITY OF LIPOSOMES - INDUCTION OF SYSTEMIC IGG AND SECRETORY IGA RESPONSES IN MICE BY INTRANASAL IMMUNIZATION WITH AN INFLUENZA SUBUNIT VACCINE AND COADMINISTERED LIPOSOMES [J].
DEHAAN, A ;
GEERLIGS, HJ ;
HUCHSHORN, JP ;
VANSCHARRENBURG, GJM ;
PALACHE, AM ;
WILSCHUT, J .
VACCINE, 1995, 13 (02) :155-162
[8]   Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers [J].
Drabick, JJ ;
Brandt, BL ;
Moran, EE ;
Saunders, NB ;
Shoemaker, DR ;
Zollinger, WD .
VACCINE, 1999, 18 (1-2) :160-172
[9]  
ELSON CO, 1999, MUCOSAL IMMUNOLOGY, P817
[10]  
Gagliardi MC, 2000, EUR J IMMUNOL, V30, P2394, DOI 10.1002/1521-4141(2000)30:8<2394::AID-IMMU2394>3.0.CO